Genetic Variation and Chronic Kidney Disease Progression

African Americans with chronic kidney disease and two copies of the APOL1 gene are more likely to progress to kidney failure, suggesting need for new screening.
Source: NIDDK News - Category: Endocrinology Source Type: news

Related Links:

The risk assessment tool from the recent Kidney Disease: Improving Global Outcomes conference adds another prediction model for the risk of developing advanced chronic kidney disease and potential need for dialysis.1 None of the existing prediction models use a patient ’s rate of loss of estimated glomerular filtration rate (eGFR). Both current eGFR and the magnitude of past eGFR decline contribute substantially to the risk of end-stage renal disease.2 Furthermore, a graph of all previous eGFR values is an effective visual aid for shared decision-making and can be a useful predictor of when clinical events and treatm...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research
Fibroblast growth factor 23 (FGF23) has appeared as a hormone that is massively elevated in patients with chronic kidney disease. Whether FGF23 is a risk factor that associates with cardiac pathologies and cardiovascular mortality, as suggested by a variety of clinical studies, or additionally acts as a causative factor that induces cardiac injury, as more recently indicated by cell culture and animal studies, is under debate and the center of many ongoing experimental studies.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
Vascular calcification is a frequent complication of advanced chronic kidney disease. Protein carbamylation is implicated in the acceleration of vascular disease in chronic kidney disease, but the mechanisms are not  clear. Mori et al. report that protein carbamylation exacerbates vascular calcification by decreasing ectonucleotide pyrophosphate/phosphodiesterase 1 expression, owing to carbamylation of mitochondrial proteins and oxidative stress. This provides new insight into the pathways responsible for cal cification in chronic kidney disease.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
TUESDAY, June 19, 2018 -- From 2008 to 2012 there was a decrease in overall rates of cardiac stress testing in Medicare beneficiaries, though rates were consistently higher for patients with chronic kidney disease (CKD) than those without CKD,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Anemia is a condition characterized by a deficiency of red blood cells (RBCs) or hemoglobin (Hb), resulting in a diminished capacity of the blood to carry and deliver oxygen to tissues and organs (Abbasi et al., 2014). Anemia is often multifactorial in etiology and may be patient- (e.g., iron-deficiencies, vitamin deficiencies), disease- (e.g., bone marrow diseases, chronic diseases, hemorrhage), or anticancer treatment- (e.g., chemotherapy, radiotherapy, precision therapies) related (Crathorne et al., 2016).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
Conclusion In a large US-based outpatient registry, we found that a quarter of adults with T2D had a diagnosis of HF, which was predominantly HFpEF. Although certain T2D medication use in patients with HF appeared consistent with evidence (less use of thiazolidinediones), others appeared contrary to evidence (less use of metformin and SGLT2 inhibitors).
Source: American Heart Journal - Category: Cardiology Source Type: research
This study characterizes the exclusion of patients with chronic kidney disease (CKD) in randomized clinical trials of drug treatment for bladder, breast, colorectal, lung, and prostate cancer.
Source: JAMA - Category: General Medicine Source Type: research
The first biosimilar to epoetin alfa for patients with anemia from chronic kidney disease, chemotherapy, or zidovudine treatment for HIV infection has receivedFDA approval.
Source: JAMA - Category: General Medicine Source Type: research
Publication date: Available online 19 June 2018 Source:American Journal of Kidney Diseases Author(s): Raymond R. Townsend This narrative review summarizes a decade of experience examining the cross-sectional and longitudinal relationships of arterial stiffness, as assessed using carotid-femoral pulse wave velocity, with outcomes in patients with chronic kidney disease enrolled in the Chronic Renal Insufficiency Cohort. Our goal is to review the importance of the pulse wave contour and pulse wave velocity and present data on the reproducibility of pulse wave velocity measurements, determinants of pulse wave velocity, and t...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: African Health | Chronic Kidney Disease | Genetics | Urology & Nephrology